MindMed Rebrands as Definium Therapeutics, Targets 2026 Trials for LSD-Based Treatments

NEW YORK – Mind Medicine (MindMed) Inc., a developer of treatments derived from psychedelics for mental health conditions, has changed its name to Definium Therapeutics Inc., a move that underscores its push into late-stage testing for anxiety and depression therapies. The company, which will begin trading under the Nasdaq symbol $DFTX on January 15, expects results from three Phase 3 studies of its lead LSD formulation in 2026, a step that could clarify the commercial path for such compounds in mainstream medicine.

The rebranding comes as Definium readies submissions to the Food and Drug Administration (FDA) for its flagship product, DT120 [formerly MM120], an orally disintegrating tablet version of lysergic acid diethylamide (LSD) designed for single-dose administration. Two trials target generalized anxiety disorder (GAD), a condition that affects 3.1% [or 6.8 million] of U.S. adults, with topline data from the Voyage Study due in the second quarter and from Panorama in the second half. A third trial, Emerge, focuses on major depressive disorder (MDD) and has accelerated ahead of schedule, with results projected for midyear. The FDA already granted breakthrough therapy status to DT120 for GAD in 2024, which fast-tracks review for drugs showing substantial improvement over existing options.

Definium’s work builds on decades of research into LSD’s effects on brain function, aiming to deliver rapid symptom relief without the chronic dosing common in current antidepressants. Chief Executive Rob Barrow described the effort as “retracing LSD to its origins” to unlock its potential as a controlled therapeutic, backed by rigorous trial designs. The company also started dosing in a Phase 2a trial of DT4023 [formerly MM402], another experimental drug, for autism spectrum disorder (ASD), with early findings slated for later this year.

This name change drops the “MindMed” branding that once evoked the company’s roots in psychedelic exploration, opting instead for “Definium,” a blend of Latin roots suggesting precise direction and boundless possibility. Stephanie Fagan, the chief corporate affairs officer, said the shift signals a commitment to “transparency, trust, and collaboration” with regulators and providers. Analysts see it as a signal of maturity. MindMed raised $242.8 million in October to fund these trials and early commercialization, positioning it to tap into established networks like those for esketamine treatments.

In the broader field of psychedelic-derived drugs, Definium’s progress stands out for its scale. While competitors like Compass Pathways test psilocybin for depression, few have advanced multiple LSD-based candidates this far, and the oral tablet format could ease adoption over supervised infusions. Yet success will depend on demonstrating durable benefits in diverse patient groups, given the historical stigma around these substances and the need for clear risk profiles in controlled settings.